Publications by authors named "G Bucaneve"
[Not Available].
Recenti Prog Med
December 2024
Aim of the study was to assess the use of pharmacological therapies provided in Nursing Homes and Protected Residences of the Umbria Region, with reference to central nervous system medications. In 2022, 200 ddd (defined daily doses) per 100 bed-days were administered in Umbria's long term care facilities, representing a 6.2% decrease compared to the previous year.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the safety and effectiveness of rituximab biosimilars compared to the original rituximab (Mabthera) in 800 patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia across 13 centers in Italy.
- Out of 505 newly diagnosed patients analyzed, 16.8% experienced adverse drug reactions (ADRs), mostly during the first and second infusions, with the common reactions being general disorders and administration site conditions.
- The results indicate that rituximab biosimilars are clinically safe and switching between different biosimilars does not increase adverse events, potentially encouraging wider use and lowering healthcare costs.
Introduction: Chronic diseases, such as hemophilia, can evoke psychological sequelae and be associated with a higher risk of mental health disorders. The utilization of antidepressant and antipsychotic drugs in subjects with hemophilia is not completely understood and few data are available.
Objectives: The aim of this analysis is to describe use of antidepressant and antipsychotic drugs in subjects with hemophilia of the Umbria Region in the period 2011-2022.
Background: KPC-K.pneumoniae bloodstream infection (KPC-KpBSI) mortality rate in patients with hematological malignancies is reported about 60%. The initial treatment active against KPC-K.
View Article and Find Full Text PDFLarge-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project.
BioDrugs
November 2021
Article Synopsis
- Biological drugs significantly enhance the treatment of immune-mediated inflammatory diseases (IMIDs), but they carry risks such as infections and cancer in real-world scenarios.
- This study aimed to assess the effectiveness of a large Italian multi-database system for tracking the safety of biological drugs and their biosimilars after market release.
- Analyzing data from 13 regional claims databases, researchers found a threefold increase in the prevalence of biological drug users from 2010 to 2019, identifying over 143,000 users with substantial cumulative exposure to these medications.